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The clinical efﬁcacy (reduction of symptoms, global assessment
by patient and physician) was similar between the two treatment
groups.
Conclusion: The IPD meta-analysis using objective parameters
(eliminationof bacteriuria) demonstrated equivalent efﬁcacy (non-
inferiority) of nitroxoline with the controls tested (cotrimoxazole,
norﬂoxacin) in the treatment of uUTI.With a ﬁve (sporadic uUTI) or
ten day (recurrent uUTI) therapy elimination of bacteriuria can be
achieved in over 90% of the patients. Considering the good safety
andefﬁcacyofnitroxoline and theworldwide increaseof resistance
of uropathogens against cotrimoxazole and ﬂuoroquinolones, but
not against nitroxoline within the last 20 years, nitroxoline should
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Background: Tuberculosis (TB) is a major cause of morbidity
andmortalityworldwide. Co-infectionwithHIVand theemergence
of drug-resistant Mycobacterium tuberculosis strains (MDR-and
XDR-TB) has reafﬁrmed TB as a global public health threat. New
therapies are urgently needed. An alternative approach to gen-
erate new TB treatment options in a timely and cost-effective
manner is “repurposing” clinically used drugs with known phar-
maceutical properties. In the course of a screening program [PMID:
21576426], we identiﬁed the in vitro anti-tuberculosis activity of
the anthelmintic avermectins (ivermectin, selamectin, moxidectin
and doramectin) [PMID: 23165468].
Methods & Materials: We performed a literature search on the
pharmacological properties of the avermectins. We integrated this
informationwith our in vitrodata and calculated a theoretical phar-
macodynamic value (AUC/MIC; a measure of drug exposure) to
deﬁne potential in vivo efﬁcacy. We validated our analysis by eval-
uating avermectins in an in vivo model of M. tuberculosis infection.
Results: An AUC/MIC ratio of 10 to 15 was calculated for
bactericidal activity of the avermectins. Due to tolerability and
pharmacokinetic issues the low maximal plasma concentrations
of ivermectin (ng/mL range) resulted in a low calculated exposure
(AUC/MIC < 1). Moxidectin had a longer half-life than ivermectin
and, therefore, the calculated AUC/MIC ratios increased. However,
this was still not enough to provide theoretical in vivo activity. In
contrast, selamectin’s pharmacokinetic properties suggest that it
might be effective in vivo against M. tuberculosis; high plasma con-
centrations (g/mL range), low toxicity (LD50 >1,600mg/kg bw),
and theoretical AUC/MIC ratios are consistentwith potential in vivo
activity. Interestingly, reported concentrations of selamectin in the
lungs (the main site where M. tuberculosis resides) were ca. 2-fold
higher than in plasma, suggesting even higher AUC/MIC ratios at
the site of infection.We therefore tested ivermectin and selamectin
for in vivo activity against M. tuberculosis. Our predictions were
consistent with the in vivo data; while ivermectin at the highest
possible safe dose did not have anti-mycobacterial activity in vivo,
selamectin was active.
Conclusion: This theoretical data analysis supports the poten-
tial of selamectin for TB therapy, including MDR- and XDR-TB, and
warrant further in vivo testing in mouse infection models.
http://dx.doi.org/10.1016/j.ijid.2014.03.841
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Background: Emphysematous osteomyelitis is a rare but ful-
minant disease. Therefore, radiologists should be aware of the
implication of intraosseous gas signs for quick diagnosis.
Methods & Materials: Case: A 55-year-old woman with dia-
betes mellitus and hypertension was admitted to the emergency
department and presented with high fever (40 ◦C), nausea, and
pelvic pain. Physical examination revealed pelvic and pubic ten-
derness on deep palpation. Laboratory data included leukocytosis
(12390/mm3 with 85.5% neutrophilis), high procalcitonin (33.8
ng/ml), C-reactiveprotein (211mg/dl) levels, a high sedimentation
rate (80mm/h), also elevated blood sugar (290mg/dl), and elevated
hemoglobin A1C level (13.4%). Blood cultures were obtained prior
to the initiation of antimicrobial therapy.
Abdominal ultrasonographic examination revealed cholelithi-
asis without gallbladder wall thickening and a small amount of
isolated pelvic free ﬂuid. A subsequent CT of her abdomen and
pelvis showed multiple gas bubbles in the medullary cavity of the
bilateral pubic bones, extending into the anterior acetabulum. A
moderate amount of gas was seen in the soft tissues surrounding
the pubis. Also, marked subcutaneous reticulation and low attenu-
ation areas of subcutaneous gas were detected in the right gluteal
region. MRI conﬁrmed the CT ﬁndings and provided clearer images
of the small abscess formations and the peripubic soft tissue com-
ponent of the infection. CT-guided biopsy of prepubic soft tissue
collection was performed, and Escherichia coli was cultured from
the diagnostic specimen.
Results: Intravenosus (IV) imipenemcilastatin (4×500mg) and
vancomycin (2×1g) was started as an empirical treatment. The
patient underwent urgent surgical debridement of the soft tissue
abscess. All samples (biopsy–surgical specimens and blood cul-
tures) revealed a monomicrobial growth of E. coli. Intravenosus
ciproﬂoxacin (2×400mg) was started based on the antibiogram
results. The ﬁrst 3 weeks of treatment was completed as IV ther-
apy. The patient was discharged with oral antibiotic treatment
(ciproﬂoxacin 2×750mg). The patient’s treatment was completed
in 6 weeks. No complications were seen and she continues to be
followed up.
